// App-Quantinova.ai

: Classifying patients as GOLD A–D using the 2017 strategy criteria: impact on efficacy by GOLD stage in the OTEMTO tiotropium+olodaterol clinical trials

Researchers

Presenter

  • Dave Singh

Principal Investigators

  • Leif Bjermer

  • Roger Abrahams

  • Lars Grnke

  • Florian Voss

  • Gary T. Ferguson

Medical Centers

  • University of Manchester, Manchester, United Kingdom

  • Skane University Hospital, Dept of Respiratory Medicine & Allergology, Lund, Sweden

  • Morgantown Pulmonary Clinical Research, Morgantown, United States of America

  • Boehringer Ingelheim Corporation, Ingelheim am Rhein, Germany

  • Pulmonary Research Institute of Southeast Michigan, Michigan, United States of America

Locations

  • United Kingdom

  • Sweden

  • United States

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • Tiotropium/olodaterol

Outcome

  • N/A

Study Design

  • Placebo Control

  • Controlled

Phase

  • III

Study Id's

  • NCT01964352

  • NCT02006732

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved